A study on the effect of an Echinacea formulation on the clinical manifestations and evolution of Covid-19.

Jesús Rodríguez Requena0 个研究点目标入组 230 人开始时间: 2021年9月1日最近更新: 2021年9月7日

适应症

试验速览

暂无简介。

•Age between 18 and 99. Capacity to provide informed consent.
•Presentation with a predominantly respiratory involvement.
•Body temperature of 37ºC, at some point in the course of the disease,
•Being between days 1 and 8 of disease course, counted from inception of symptoms
•Npt being vaccinated against SARS_COV-2.
•Being able to complete the treatment, in particular, swallowing the caplets.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 140
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 90

•Patients without a PCR or antigen test-based diagnosis.
•Asymptomatic patients.
•Patients with a disease course of more than 9 days
•Patients with a predominantly digestive presentation.
•Patients with a formal counterindication to take echinacea.
•Patients that have previously received oxygen therapy.
•Non collaborative patients, patients under 18, or unable to provide informed consent

发起方

Jesús Rodríguez Requena